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Detection of the Novel optrA Gene
Among Linezolid-Resistant Enterococci in Barcelona, Spain
Jordi Càmara,1 Mariana Camoez,1,2 Fe Tubau,1,3 Miquel Pujol,2,4 Josefina Ayats,1,3
Carmen Ardanuy,1,3 and M. Ángeles Domı́nguez1,2
The purpose of this study was to describe the presence of the novel optrA gene among clinical isolates of
enterococci in a Spanish teaching hospital (May 2016–April 2017). optrA and cfr genes were screened by PCR
in all isolates showing linezolid minimal inhibitory concentration (MIC) ‡4 mg/L. The genetic relatedness of
the isolates, the presence of resistance and virulence genes, and the genetic environment of optrA were assessed
by whole-genome sequencing (WGS). Six of 1,640 enterococci had linezolid MIC ‡4 mg/L. Among them, the
optrA gene was detected in five Enterococcus faecalis isolated from unrelated patients. Although none of them
had received linezolid or chloramphenicol, all had antecedents of recent quinolone consumption. WGS analysis
revealed the existence of two different genotypes: ST585 and ST474. cfr was not detected in any of the isolates.
No mutations were detected among the 23S ribosomal RNA and the ribosomal proteins L3, L4, and L22. Both
genotypes also carried genes related to aminoglycoside, lincosamide, macrolide, phenicol, and tetracycline
resistance. Detection of optrA in a setting with low linezolid consumption and among patients without ante-
cedents of oxazolidinone therapy is of concern.
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Introduction
L inezolid resistance is emerging as a problem in thetreatment of multidrug-resistant Gram-positive organ-
isms, particularly methicillin-resistant Staphylococcus aureus
and vancomycin-resistant Enterococcus faecium.1,2 Among
enterococci, linezolid resistance is mainly mediated by chro-
mosomal mutations in domain V of the 23S ribosomal RNA
(rRNA).3 However, a transferable oxazolidinone resistance
gene (cfr), which encodes a methyltransferase that modifies
the 23S rRNA, was described in 2001.4 This gene confers
resistance to linezolid, phenicols, lincosamides, pleuromutilins,
and streptogramin A. Recently, a novel mechanism (optrA) was
described in Enterococcus spp.,5–12 Staphylococcus sciuri,13,14
and Streptococcus suis,15 indicating its ability to spread to
different genus. optrA encodes an ABC-F protein that pro-
tects the bacterial ribosome from the antibiotic inhibition,
has the ability to spread through plasmids, and confers re-
sistance to linezolid and phenicols.5,16
In our setting, Hospital Universitari de Bellvitge (HUB),
linezolid resistance is rare (<1% in both enterococci and
staphylococci) and the cfr gene has been sporadically de-
tected in S. aureus.17 The purpose of this study was to screen
for the presence of transferable linezolid resistance among
linezolid-resistant clinical isolates of enterococci in a tertiary
care hospital in Barcelona, Spain.
Materials and Methods
Study setting, bacterial isolates, and antimicrobial
susceptibility testing
This study was performed at HUB, a 700-bed teaching
hospital located in the urban area of Barcelona, Spain. From
May 2016 to April 2017, all enterococci isolates obtained
from clinical samples were routinely identified by Matrix-
Assisted Laser Desorption/Ionization-Time of Flight Mass
Spectrometry (MALDI-TOF MS) (Bruker Daltonik GmbH,
Bremen, Germany) and tested for antimicrobial susceptibility
by microdilution (Microscan; Beckman Coulter, Brea, CA)
following the Clinical and Laboratory Standards Institute
(CLSI) recommendations and criteria.18 The linezolid minimal
inhibitory concentration (MIC) breakpoints were as follows:
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susceptible £2 mg/L, intermediate 4 mg/L, and resistant ‡8 mg/
L. Isolates showing linezolid MIC ‡4 mg/L were further
studied by microdilution, using Sensititre Rapmyco plates
(Thermo Fisher Scientific, Waltham, MA) with linezolid
concentrations ranging from 1 to 32 mg/L.
Molecular characterization
Linezolid-resistant isolates were screened for both cfr
and optrA genes by PCR, as described elsewhere.7 Whole-
genome sequencing (WGS) was performed in those optrA-
positive isolates. Libraries were prepared (NexteraXT)
and multiplexed in an MiSeq run (150 bp paired-reads).
Reads were processed using Geneious 9.1.7 (Biomatters,
Auckland, New Zealand): duplicate reads were removed,
ends were trimmed, and reads were de novo assembled
using the Geneious assembler with default settings (me-
dium sensitivity). The genetic environment of optrA was
in silico studied comparing those contigs containing the
optrA gene with those previously published. The existence
of resistance and virulence genes and the genetic relat-
edness of the isolates were studied through the online tools
Resfinder 2.1, Virulence finder 1.5, and CSI phylogeny (www
.genomicepidemiology.org/, last accessed June 15). This last
analysis included, for comparative purposes, all previously
sequenced optrA-positive Enterococcus faecalis strains (Sup-
plementary Table S1; Supplementary Data available online
at www.libertpub.com/mdr). Data from WGS were also used
to search for chromosomal mutations related to oxazolidinone
(23S rRNA and ribosomal proteins L3, L4, and L22) and
quinolone (GyrA and ParC proteins) resistance. E. faecalis
ATCC 29212 (accession number CP008816) was used as
reference strain. Raw data were deposited to the European
Nucleotide Archive (www.ebi.ac.uk/ena) with accession
numbers ERS1788479–1788483.
Clinical data
Clinical data of patients were retrospectively reviewed
from electronic records. Data included age, sex, admission
ward, previous antimicrobial therapy, treatment, and out-
come. This study was approved by the Clinical Research
Ethics Committee of HUB (PR354/17). As no intervention
was involved and patients’ identification was anonymized,
written informed consent was considered not necessary.
Results
During the study period, 1,640 enterococci isolates were
collected from clinical samples of 1,249 patients. Table 1
gives the species and the linezolid MICs of the studied
population. Overall, 1,634 isolates (99.6%) had MIC £2 mg/L
and only 6 E. faecalis (0.4%) were linezolid nonsusceptible
(MIC ‡4 mg/L). In our series, E. faecalis isolates had sig-
nificantly higher linezolid MICs than E. faecium ( p < 0.01).
After PCR screening, the optrA gene was detected in five of
these nonsusceptible isolates, all showing chloramphenicol
MIC of >256 mg/L (Table 2). We did not detect the cfr gene
in any of the isolates. All five isolates were recovered from
urine samples of five male patients admitted to three different
wards. Two patients had clinical symptoms of urinary tract
infection and were successfully treated with aminopenicillins
(ampicillin and amoxicillin). The remaining three patients
were asymptomatic and their isolates were obtained from low
urinary bacterial counts. Consequently, these isolates were
considered colonizing and the patients did not receive anti-
microbial therapy. As we did not find any epidemiological
relationships between these five patients, these acquisitions
were considered unrelated. Although none of them had re-
ceived oxazolidinones or phenicols, all had antecedents of
recent (<6 months) antimicrobial therapy.
As deduced from WGS, isolates belonged to two sequence
types (ST474 and ST585) that were also discriminated by the
single-nucleotide polymorphism (SNP) analysis: SNP differ-
ences were 502 among ST474 isolates, ranged from 140 to
300 among ST585 isolates, and were *15,000 between both
groups (Supplementary Table S2). Overall, the WGS analysis
of E. faecalis carrying optrA displayed high genetic diversity,
including, as defined by multilocus sequence typing (MLST),
12 different genotypes (Fig. 1 and Supplementary Table S1).
With regard to the isolates presented in this study, although
ST585 strains carrying optrA have been described from
human samples in China,5,6 we could not find any report of
ST474. This sequence type that was added to the MLST
webpage (www.mlst.net) from the Chinese Guangdong
province (liver sample from a pig) shares four of seven
MLST alleles with ST59. Interestingly, although this ST59
was first reported from a Spanish pig in 2001,19 it has been
recently detected among optrA-positive isolates in China
(human and animal sources)5,6 and Colombia (poultry meat).8
Data from WGS confirmed this relationship showing that
ST474 isolates were related to the ST59 Colombian isolates
(12E and 34E) and to an additional isolate collected in Ma-
laysia in 2012 (Enfs85).
Investigation of acquired resistance genes revealed that
all isolates carried genes encoding resistance to tetracy-
clines, macrolides, lincosamides, streptogramin B, and phe-
nicols (Table 2). Four isolates shared the OptrA wild type,
originally described in E. faecalis E394, whereas one ST474
isolate had an amino acid substitution (Tyr176Asp).6 All
strains harbored cat (cat A-8) and fexA genes, both related
Table 1. Enterococcus Species and Linezolid




number of isolates (%)
<1 2 4 >4
E. avium 12 (85.7) 2 (14.3)
E. casseliflavus 2 (66.7) 1 (33.3)
Enterococcus
faecalis
703 (59.0) 483 (40.5) 2 (0.2) 4 (0.3)
Enterococcus
Faecium
289 (70.0) 124 (30.0)
E. gallinarum 4 (66.7) 2 (33.3)
E. hirae 1 (25.0) 3 (75.0)
E. raffinosus 4 (100)
Other 2 (50.0) 2 (50.0)
All 1,017 (62.0) 617 (37.6) 2 (0.1) 4 (0.2)
Only species accounting for more than two isolates are given.
CLSI linezolid MIC breakpoints were as follows: susceptible
£2 mg/L, intermediate 4 mg/L, and resistant ‡8 mg/L.18
MIC, minimal inhibitory concentration; CLSI, Clinical and Lab-
oratory Standards Institute.

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































to phenicol resistance. No mutations were detected among
the 23S rRNA and ribosomal proteins L3, L4, and L22. One
ST585 isolate and all ST474 isolates carried the aac(6¢)-
aph(2¢¢) gene, conferring high-level resistance to gentamicin.
All isolates showed amino acid substitutions related to qui-
nolone resistance20 in ParC (Ser80Ile) and GyrA (Ser83Phe
and Glu87Gly in ST585 and ST474 isolates, respectively).
Both genotypes shared a high number of virulence factors
including genes related to adhesion (ace, agg, efaAfs, and
elrA), biofilm production (ebpA, ebpB, and ebpC), proteases
(gelE and srtA), protection against oxidative stress (tpx), and
genes involved in quorum sensing (cad, camE, cCF10, cOB1,
and fsrB). Main differences were the existence of the cyto-
lysin operon (cylA, cylB, cylL, and cylM genes) only in ST585
and the presence of hyaluronidase genes hylA and hylB only
in ST474. As both STs were responsible for episodes of not
only infection but also colonization, we could not hypothesize
about the importance of these factors in the pathogenesis of
isolates.
Finally, the genetic environment of the optrA gene was
in silico compared with previously published data and, in
agreement with that, all ST585 isolates harbored a genetic
context identical to that reported from plasmid pXY17 (de-
scribed in ST585 isolates from China). Isolate 4 (ST474)
showed a structure related to plasmid p10-2-2, which is in
agreement with the fact that this plasmid was found in an
ST59 isolate, genetically related to ST474.10 Isolate 5 showed
truncated contigs and the region could only be partially re-
vealed (Fig. 2).
Discussion
The frequent detection of optrA among Chinese isolates
of animal origin suggests their selection by the use of an-
tibiotics in animals (florfenicol), or indirectly by other an-
tibiotics for human uses whose resistance mechanisms are
harbored by the same plasmids. A previous study found a
high prevalence of linezolid resistance genes in soils next to
FIG. 1. SNP phylogenetic tree of
Enterococcus faecalis carrying optrA.
The scale bar represents the genetic
divergence between isolates (number
of SNPs/total number of polymorphic
sites). The figure includes isolates
reported in this study (isolates 1–5),
previously published isolates, and
WGS sequences of optrA-positive
E. faecalis obtained after performing a
blast search in the NCBI public data-
base (Table S1). SNP, single-
nucleotide polymorphism; WGS,
whole-genome sequencing.












































pig farms in China, including both cfr and optrA genes,
establishing a clear link between resistance and livestock
farming.21 In addition, the recent report of optrA from a
human-related lineage of E. faecalis (ST86) in urban waste-
water (Tunisia) suggests the existence of effective dissemi-
nation in the human setting.22 Data from European countries
and the United States are still scarce. In Europe, a few optrA-
positive enterococci isolates have been reported.7,11,12,23 A
recent multicenter study carried out on isolates from 42
countries, excluding the United States, detected the optrA
gene in 9 isolates (8 E. faecalis and 1 S. gallolyticus) from
a large sample of 854 enterococci and 469 viridans-group
streptococci screened.24 In a linezolid surveillance pro-
gram in the United States, the optrA gene was found in 2
E. faecalis of 973 enterococci screened.25
This is the first detection of optrA in Spain, as far as is
known. As linezolid consumption is low in our setting, and
none of the patients harboring optrA-positive isolates re-
ceived linezolid or chloramphenicol therapy, our findings are
of concern. As reported, the coexistence of other resistance
markers in the same mobile genetic elements could justify the
role of antimicrobials other than oxazolidinones or phenicols
in spreading these strains.5 Although we were not able to find
optrA and other resistance genes colocated in the same ge-
netic environment (with the exception of fexA), their as-
sociation cannot be excluded from our data. Therefore,
other antimicrobials for human use (i.e., macrolides, qui-
nolones, tetracyclines, or streptomycin) could contribute
to the selection of these isolates in the clinical setting. In
this respect, it is remarkable that all isolates were resistant
to ciprofloxacin and this was because of a nontransferable
mechanism. Data on antibiotic consumption from our hos-
pital indicate that, after penicillins, quinolones are the second
group of most prescribed antimicrobials (10.74 prescribed
daily doses per 100 patient-days in 2015), substantially ex-
ceeding the consumption of linezolid (0.48 daily doses per
patient-day in 2015). The fact that all isolates were recovered
from urine samples and all patients had antecedents of qui-
nolones consumption, which are frequently used in urine tract
infections, could indicate that, in our clinical setting, these
antibiotics may have played an important role in the selection
of these isolates. In fact, quinolones have already been in-
volved in mechanisms of antimicrobial resistance co-selection
among Gram-negative bacteria.26 Although optrA has not
been clearly linked to any case of clinical failure after line-
zolid treatment, its presence in the hospital setting is worri-
some. As no evidence of chromosomal mutations related to
linezolid resistance were detected (that are usually associ-
ated to linezolid utilization),27 it seems that the emergence of
optrA isolates in our setting is independent of oxazolidinone
consumption. In addition, the detection of different genotypes
isolated from apparently unrelated patients could be an in-
direct sign of its dissemination in our region and beyond the
hospital setting, which needs to be clarified in further studies.
Our study adds epidemiological information on trans-
ferable linezolid resistance. Data obtained from WGS are
particularly useful for assessing genetic relatedness among
bacteria, allowing data sharing worldwide. The study of pre-
viously published WGS sequences of optrA-positive E. fae-
calis reveals the existence of multiple lineages and worldwide
distribution. Specifically, WGS allowed us to put in con-
text our clinical isolates and to establish genetic relation-
ship between the two of them (isolates 4 and 5), an isolate
from animal origin (Malaysia, 2012) and two isolates from
poultry meat (Colombia, 2011).8 WGS is not able to solve
the origin of this association. However, the fact that these
isolates were obtained from both human and animal origin
in several different countries indicates the existence of a
wide distribution of optrA. As isolates belonging to ST59
have been described before the optrA description in ani-
mals19,28 and also in the clinical setting,29 the ability of this
lineage to cause invasive human disease is evident. Actually,
this goes in line with the high number of virulence factors
detected, most of them also shared by ST585 isolates.
Our study has limitations. As we only included isolates
showing linezolid MIC ‡4 mg/L, and optrA has been detected
in isolates with lower MICs,5,7,9,13 our findings could under-
estimate its presence. This could be especially important in
environments with higher linezolid consumption and higher
resistance rates that could masquerade the presence of this
mechanism. In addition, although WGS is a powerful epide-
miological tool, complete plasmid sequences are difficult to
assemble through short reads giving only partial results that
makes the analysis of these genetic elements difficult.30
FIG. 2. Graphic representation of the genetic environment of optrA containing regions. Contigs containing optrA were
compared with previously published regions and then reads were mapped against these regions. Isolates 1, 2, and 3 (ST585)
shared the same genetic environment described in plasmid pXY17 and isolate 4 (ST474) showed a structure related to
plasmid p10-2-2. The structure of the region containing optrA of isolate 5 could only be partially revealed.












































In conclusion, we report the presence of optrA among
clinical linezolid-resistant isolates in an urban area of
Barcelona that is not related to linezolid consumption. Ac-
tive surveillance and continued efforts to control the use of
antimicrobials in veterinary and clinical practice are needed
worldwide. Otherwise, the arsenal of available antimicrobial
drugs against infections caused by multidrug resistance could
be significantly reduced.
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